RICHMOND, Calif., Aug. 31, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will provide an update on the Company's therapeutic development programs at the following conferences in September.

https://photos.prnewswire.com/prnvar/20130102/SF35903LOGO


    --  2016 Wells Fargo Healthcare Conference, Boston, MA, September 7-8, 2016
        --  Dr. Macrae is scheduled to present at 9:20 am ET on Wednesday,
            September 7(th).
    --  BioCentury 23(rd) Annual NewsMakers in the Biotech Industry, New York,
        NY, September 9, 2016
        --  Dr. Macrae is scheduled to present at 9:00 am ET on Friday,
            September 9(th).

The presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentation. The presentations will be archived on the Sangamo website for two weeks after the event.

About Sangamo
 Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures(®) for monogenic and infectious diseases by deploying its novel zinc finger DNA-binding protein technology, in therapeutic genome editing and gene regulation, and AAV-based gene therapy platforms. The Company's proprietary In Vivo Protein Replacement Platform(TM) (IVPRP) approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders. Based on its proprietary IVPRP approach, Sangamo is initiating a Phase 1/2 clinical trial for hemophilia B, the first in vivo genome editing application cleared by the FDA. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics(®) for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.

ZFP Therapeutic(®) is a registered trademark of Sangamo BioSciences, Inc.

Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-participation-at-upcoming-investor-conferences-300320906.html

SOURCE Sangamo BioSciences, Inc.